Compare ALEMBIC LTD with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs NATCO PHARMA - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD NATCO PHARMA ALEMBIC LTD/
NATCO PHARMA
 
P/E (TTM) x 73.7 15.4 478.8% View Chart
P/BV x 2.6 3.0 86.6% View Chart
Dividend Yield % 0.4 1.5 26.4%  

Financials

 ALEMBIC LTD   NATCO PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
NATCO PHARMA
Mar-18
ALEMBIC LTD/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs721,080 6.7%   
Low Rs34671 5.0%   
Sales per share (Unadj.) Rs4.7592.1 0.8%  
Earnings per share (Unadj.) Rs6.1188.4 3.2%  
Cash flow per share (Unadj.) Rs6.2206.3 3.0%  
Dividends per share (Unadj.) Rs0.208.25 2.4%  
Dividend yield (eoy) %0.40.9 40.1%  
Book value per share (Unadj.) Rs40.7833.6 4.9%  
Shares outstanding (eoy) m267.0336.90 723.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x11.31.5 761.7%   
Avg P/E ratio x8.74.6 186.7%  
P/CF ratio (eoy) x8.54.2 199.8%  
Price / Book Value ratio x1.31.1 124.0%  
Dividend payout %3.34.4 74.8%   
Avg Mkt Cap Rs m14,13932,311 43.8%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m2073,256 6.4%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m1,25521,848 5.7%  
Other income Rs m370404 91.6%   
Total revenues Rs m1,62522,252 7.3%   
Gross profit Rs m1119,284 1.2%  
Depreciation Rs m38662 5.7%   
Interest Rs m2154 1.1%   
Profit before tax Rs m4428,872 5.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m241,920 1.2%   
Profit after tax Rs m1,6306,952 23.4%  
Gross profit margin %8.942.5 20.8%  
Effective tax rate %5.421.6 25.0%   
Net profit margin %129.831.8 408.1%  
BALANCE SHEET DATA
Current assets Rs m1,86721,307 8.8%   
Current liabilities Rs m5915,920 10.0%   
Net working cap to sales %101.670.4 144.3%  
Current ratio x3.23.6 87.7%  
Inventory Days Days9473 128.7%  
Debtors Days Days74107 69.1%  
Net fixed assets Rs m1,79114,986 12.0%   
Share capital Rs m534369 144.7%   
"Free" reserves Rs m10,32430,353 34.0%   
Net worth Rs m10,85830,760 35.3%   
Long term debt Rs m410-   
Total assets Rs m11,59137,151 31.2%  
Interest coverage x260.958.6 445.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.6 18.4%   
Return on assets %14.119.1 73.6%  
Return on equity %15.022.6 66.4%  
Return on capital %15.229.3 51.8%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1910,322 0.2%   
Fx outflow Rs m2642,978 8.9%   
Net fx Rs m-2447,343 -3.3%   
CASH FLOW
From Operations Rs m2364,636 5.1%  
From Investments Rs m-224-11,155 2.0%  
From Financial Activity Rs m-276,509 -0.4%  
Net Cashflow Rs m-15-18 82.2%  

Share Holding

Indian Promoters % 64.0 52.0 123.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.2 7.8 2.6%  
FIIs % 9.7 16.6 58.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 26.0 100.4%  
Shareholders   54,701 25,395 215.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  SUVEN LIFESCIENCES  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 19, 2019 03:35 PM

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS